Nevertheless, single TIGIT blockade achieved no or moderate anti-tumor efficacy in experimental tumor models (37, 52, 58, 64) and in enhancing in vitro functionality of human tumor-infiltrating CD8+ T cells (31). Here, CD8A is linked to neoplasm.